Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 81

Cited In for PubMed (Select 11940542)


Mean Platelet Volume as a Predictor of One-Year Major Adverse Cardiac Events following Elective Percutaneous Coronary Interventions.

Nozari Y, Bahrehmand M, Hosseini SK, Mahmoodian M, Sharafi A.

J Tehran Heart Cent. 2014;9(2):64-9.


Antiplatelet resistance and the role of associated variables in stable patients treated with stenting.

Uzun F, Biyik I, Akturk IF, Erturk M, Yalcin AA, Surgit O, Oner E, Pusuroglu H, Birand A.

Postepy Kardiol Interwencyjnej. 2015;11(1):19-25. doi: 10.5114/pwki.2015.49180. Epub 2015 Mar 6.


Cardiac thromboxane A2 receptor activation does not directly induce cardiomyocyte hypertrophy but does cause cell death that is prevented with gentamicin and 2-APB.

Touchberry CD, Silswal N, Tchikrizov V, Elmore CJ, Srinivas S, Akthar AS, Swan HK, Wetmore LA, Wacker MJ.

BMC Pharmacol Toxicol. 2014 Dec 17;15:73. doi: 10.1186/2050-6511-15-73.


Methodological issues and recommendations for systematic reviews of prognostic studies: an example from cardiovascular disease.

Dretzke J, Ensor J, Bayliss S, Hodgkinson J, Lordkipanidzé M, Riley RD, Fitzmaurice D, Moore D.

Syst Rev. 2014 Dec 3;3:140. doi: 10.1186/2046-4053-3-140.


Effect of opium addiction on aspirin resistance in stable angina pectoris.

Forood A, Malekpour-Afshar R, Sarnevesht J.

Addict Health. 2014 Winter;6(1-2):7-13.


Circulating myeloid-related protein-8/14 is related to thromboxane-dependent platelet activation in patients with acute coronary syndrome, with and without ongoing low-dose aspirin treatment.

Santilli F, Paloscia L, Liani R, Di Nicola M, Di Marco M, Lattanzio S, La Barba S, Pascale S, Mascellanti M, Davì G.

J Am Heart Assoc. 2014 Jul 18;3(4). pii: e000903. doi: 10.1161/JAHA.114.000903.


Urinary eicosanoid metabolites in HIV-infected women with central obesity switching to raltegravir: an analysis from the women, integrase, and fat accumulation trial.

Hulgan T, Boger MS, Liao DH, McComsey GA, Wanke CA, Mangili A, Walmsley SL, McCreath H, Milne GL, Sanchez SC, Currier JS, Lake JE.

Mediators Inflamm. 2014;2014:803095. doi: 10.1155/2014/803095. Epub 2014 Jun 1.


Aspirin influences megakaryocytic gene expression leading to up-regulation of multidrug resistance protein-4 in human platelets.

Massimi I, Guerriero R, Lotti LV, Lulli V, Borgognone A, Romani F, Barillà F, Gaudio C, Gabbianelli M, Frati L, Pulcinelli FM.

Br J Clin Pharmacol. 2014 Dec;78(6):1343-53. doi: 10.1111/bcp.12432.


Impact of platelet transfusion on survival of patients with intracerebral hemorrhage after administration of anti-platelet agents at a tertiary emergency center.

Suzuki Y, Kitahara T, Soma K, Konno S, Sato K, Suzuki S, Oka H, Yamada M, Fujii K, Kitahara Y, Yamamoto Y, Otsuka T, Sugiura Y, Kanoh Y, Tamai Y, Ohto H.

PLoS One. 2014 May 28;9(5):e97328. doi: 10.1371/journal.pone.0097328. eCollection 2014.


Platelet thromboxane (11-dehydro-Thromboxane B2) and aspirin response in patients with diabetes and coronary artery disease.

Lopez LR, Guyer KE, Torre IG, Pitts KR, Matsuura E, Ames PR.

World J Diabetes. 2014 Apr 15;5(2):115-27. doi: 10.4239/wjd.v5.i2.115. Review.


Network reconstruction of platelet metabolism identifies metabolic signature for aspirin resistance.

Thomas A, Rahmanian S, Bordbar A, Palsson BØ, Jamshidi N.

Sci Rep. 2014 Jan 29;4:3925. doi: 10.1038/srep03925.


Platelet content of nitric oxide synthase 3 phosphorylated at Serine 1177 is associated with the functional response of platelets to aspirin.

Modrego J, Azcona L, Martín-Palacios N, Zamorano-León JJ, Segura A, Rodríguez P, Guerra R, Tamargo J, Macaya C, López-Farré AJ.

PLoS One. 2013 Dec 20;8(12):e82574. doi: 10.1371/journal.pone.0082574. eCollection 2013.


Fatty acids and TxA(2) generation, in the absence of platelet-COX-1 activity.

DeFilippis AP, Rai SN, Cambon A, Miles RJ, Jaffe AS, Moser AB, Jones RO, Bolli R, Schulman SP.

Nutr Metab Cardiovasc Dis. 2014 Apr;24(4):428-33. doi: 10.1016/j.numecd.2013.08.012. Epub 2013 Oct 23.


Promises and challenges of pharmacogenetics: an overview of study design, methodological and statistical issues.

Ross S, Anand SS, Joseph P, Paré G.

JRSM Cardiovasc Dis. 2012 Apr 5;1(1). pii: cvd.2012.012001. doi: 10.1258/cvd.2012.012001. Review.


Comparative efficacy of in vitro and in vivo metabolized aspirin in the DeBakey ventricular assist device.

Sheriff J, Girdhar G, Chiu WC, Jesty J, Slepian MJ, Bluestein D.

J Thromb Thrombolysis. 2014 May;37(4):499-506. doi: 10.1007/s11239-013-0997-6.


Effects of low-dose aspirin and fish oil on platelet function and NF-kappaB in adults with diabetes mellitus.

Block RC, Abdolahi A, Smith B, Meednu N, Thevenet-Morrison K, Cai X, Cui H, Mousa S, Brenna JT, Georas S.

Prostaglandins Leukot Essent Fatty Acids. 2013 Jul;89(1):9-18. doi: 10.1016/j.plefa.2013.03.005. Epub 2013 May 7.


Towards personalized medicine based on platelet function testing for stent thrombosis patients.

Godschalk TC, Hackeng CM, Ten Berg JM.

Thrombosis. 2012;2012:617098. doi: 10.1155/2012/617098. Epub 2012 Dec 25.


Historical lessons in translational medicine: cyclooxygenase inhibition and P2Y12 antagonism.

Fitzgerald DJ, Fitzgerald GA.

Circ Res. 2013 Jan 4;112(1):174-94. doi: 10.1161/CIRCRESAHA.111.300271.


Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin.

Grosser T, Fries S, Lawson JA, Kapoor SC, Grant GR, FitzGerald GA.

Circulation. 2013 Jan 22;127(3):377-85. doi: 10.1161/CIRCULATIONAHA.112.117283. Epub 2012 Dec 4.


Pharmacological characterization of 1-nitrosocyclohexyl acetate, a long-acting nitroxyl donor that shows vasorelaxant and antiaggregatory effects.

Donzelli S, Fischer G, King BS, Niemann C, DuMond JF, Heeren J, Wieboldt H, Baldus S, Gerloff C, Eschenhagen T, Carrier L, Böger RH, Espey MG.

J Pharmacol Exp Ther. 2013 Feb;344(2):339-47. doi: 10.1124/jpet.112.199836. Epub 2012 Dec 4.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk